Health Care·Biotechnology·$2.1B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.85 | N/A | -32.91% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $-0.85 | N/A | -32.91% |
| Revenue | N/A | N/A | N/A |
Tone: Defensive
Management acknowledged the difficulties faced this quarter but remains focused on long-term goals. They did not provide specific guidance for the future.
Management highlighted ongoing challenges in meeting financial expectations.
They emphasized their commitment to advancing their pipeline despite the current losses.
Sarepta Therapeutics reported a larger-than-expected loss in EPS, which typically raises concerns among investors. However, the stock rose by 8.31%, likely driven by optimism around their ongoing projects and potential future developments. The lack of revenue data and guidance may leave some investors cautious, but the market seems to be reacting positively to the company's long-term vision.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
BWX TECHNOLOGIES INC
Feb 25, 2019